Person:
SARIHAN, SÜREYYA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

SARIHAN

First Name

SÜREYYA

Name

Filters

2020 - 20212
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Relationship between pet/ct response and survival in patients with non-small-cell lung cancer treated with definitive chemoradiotherapy
    (Akad Doktorlar Yayınevi, 2021-01-01) Sarıhan, Süreyya; Bilgin, Gökçe Beige; Sığırlı, Deniz; SARIHAN, SÜREYYA; Bilgin, Gökçe Beige; SIĞIRLI, DENİZ; Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Nükleer Tıp Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı; 0000-0003-4816-5798; AAH-4970-2021; EMG-1218-2022; AAA-7472-2021
    We aimed to evaluate the relationship between PET/CT response and survival in patients with non-small cell lung cancer (NSCLC) treated with curative chemoradiotherapy. Between January and December 2012, 51 patients were treated. The median age was 61 (29-79) and the M/F ratio was 46/5. Eighty two percent of the cases were stage III and 53% were squamous cell carcinoma. Median 6300 cGy (4860-7525) radiotherapy delivered and 92% of patients received chemotherapy. The median follow-up was 27 months (7-96 months) in November 2019. The objective response was 71% with CT at 1 month and 76% with PET/CT at 3 months. There was a significant correlation between response-1 and response-3 (p< 0.001). Tumor SUVmean3 < 2.81, SUVmax change >= 70% was associated with response-1 (p< 0.05). The median and 5-year overall (OS) and progression-free (PFS) survival rates were 54 months, 40% and 35 months, 38%, respectively. In Cox model, for each 1 unit increase, SUVmeanbase (HR: 1.18, 95% CI: 1.01-1.38) and SUVmean3 (HR: 2.65, 95% CI: 1.24-5.66) were found unfavorable factors for OS, whereas SUVmean3 (HR: 2.01, 95% CI: 1.02-3.93) was also found to be a poor prognostic factor for PFS. PET/CT parameters can be used as useful markers for prognosis in patients with NSCLC undergoing curative chemoradiotherapy. It is believed that early assessment during and after treatment can be advantageous in terms of treatment modification.
  • Thumbnail Image
    Publication
    Radiotherapy in patients with trachea tumours: A retrospective study and literature review
    (Kare Yayınevi, 2020-01-01) Sarihan, Süreyya; Bayram, Ahmet Sami; Melek, Hüseyin; Gebitekin, Cengiz; SARIHAN, SÜREYYA; BAYRAM, AHMET SAMİ; MELEK, HÜSEYİN; GEBİTEKİN, CENGİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı.; 0000-0003-4816-5798; 0000-0003-0684-0900; AAE-1069-2022; AAI-5039-2021; JCE-0097-2023; ABB-7580-2020; AAH-4970-2021
    OBJECTIVEIn this study, we aimed to evaluate our patients with tracheal tumours treated with primary or adjuvant radiotherapy (RT) and to review the current literature on the subject.METHODSBetween 1998 and 2017, eight patients underwent RT. Their median age was 37 years (15-53). The diagnosis was adenoid cystic carcinoma in five patients, squamous cell carcinoma in three patients and mucoepidermoid carcinoma in one patient. Resection type was R0 (1), R1 (4), R2 (1), and biopsy (2). The median tumour size was 2.6 cm (2-5). Median 59.4 Gy RT (32.4-66.6) was given, and weekly cisplatin was administered to four patients concomitantly.RESULTSWith a median follow-up of 85 months (4-189), five patients were alive. The 5-year overall and disease-free survival rates were 83% and 67%, respectively. There was no local recurrence in any patient. In one patient who had a complete response with curative chemo-RT, dilatation was performed five times in 10 years because tracheal stenosis developed at 60 months.CONCLUSIONTrachea tumours are rare, and the primary treatment is surgery. Adjuvant RT is controversial in R0 cases. In unresectable cases, RT is the primary treatment modality. We believe that our treatment results will contribute to the literature on the subject.